Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Re: Neonatal Nitric Oxide Use: Predictors of Response and Financial Implications

Journal of Perinatology volume 24, page 132 (2004)Cite this article

To the Editor:

I read with great interest the article by Truog et al.1 in which they report on the clinical predictors and financial implications of the availability of inhaled nitric oxide (INO) for the treatment of neonatal pulmonary hypertension in term and near-term infants. They report that use of INO resulted in net financial “savings” of $10,170 per patient (i.e. $895,000 for 88 reported neonates). I, however, feel that there is flaw in the methodology adopted by the authors in the calculation of the “savings” resulting from the use of INO.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Truog WE, Castor CA, Sheffield MJ . Neonatal nitric oxide use: predictors of response and financial implications. J Perinatol 2003;23(2):128–132.

    Article  CAS  Google Scholar 

  2. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. The Neonatal Inhaled Nitric Oxide Study Group. N Engl J Med 1997;336(9):597–604.

  3. Roberts Jr. JD, Fineman JR, Morin III FC, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med 1997;336(9):605–610.

    Article  CAS  Google Scholar 

  4. Davidson D, Barefield ES, Kattwinkel J, et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose–response, multicenter study. The I-NO/PPHN Study Group. Pediatrics 1998;101(3 Part 1):325–334.

    Article  CAS  Google Scholar 

  5. Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 2000;342(7):469–474.

    Article  CAS  Google Scholar 

  6. Day RW, Lynch JM, White KS, Ward RM . Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension. Pediatrics 1996;98(4 Part 1):698–705.

    CAS  Google Scholar 

  7. Jacobs P, Finer NN, Robertson CM, Etches P, Hall EM, Saunders LD . A cost-effectiveness analysis of the application of nitric oxide versus oxygen gas for near-term newborns with respiratory failure: results from a Canadian randomized clinical trial. Crit Care Med 2000;28(3):872–878.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Associate Neonatologist, Clinical Research Design & Statistical Analysis, Children's Hospital of Michigan & Hutzel Women's Hospital, Assistant Professor of Pediatrics, Wayne State University, 3901 Beaubien Blvd, 4H42, Detroit, 48201, MI, USA

    Beena G Sood MD, MS

Authors
  1. Beena G Sood MD, MS
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sood, B. Re: Neonatal Nitric Oxide Use: Predictors of Response and Financial Implications. J Perinatol 24, 132 (2004). https://doi.org/10.1038/sj.jp.7211032

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.jp.7211032

Search

Advanced search

Quick links